RNAgene Inc., established in 2018 and based in Seoul, South Korea, is a pioneering biotechnology company specializing in the development of mRNA-based therapeutics. The company has developed its proprietary mRNA-LNP platform and focuses on creating innovative solutions for various medical needs, including prophylactic and therapeutic vaccines, immuno-oncologic drugs, and treatments for infectious diseases

mRNA-LNP Platform: RNAgene has developed its own mRNA-lipid nanoparticle (LNP) platform, with strengths in optimizing Open Reading Frame (ORF) and Untranslated Region (UTR) RPiC (RNA Panning in Cell): A screening technology for selecting stabilized mRNA in cells, invented by RNAgene and patent-pending in Korea SCALUTIS (Soluble Chimeric Antigen Ligand using Trained Immune System): A platform technology that maximizes immune cell activity to target infected cells

Private

Biotech